Angiodynamics reports fiscal 2022 second quarter financial results; reaffirms revenue guidance; revises gross margin and adjusted eps guidance

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2022, which ended november 30, 2021. “we are pleased with our continued strong revenue growth as our team navigates this dynamic macro environment and manages through persistent covid headwinds,” commented jim clemmer, presiden
ANGO Ratings Summary
ANGO Quant Ranking